Pozza, R. Sub-investigator. "A Phase 3, Randomized, Open-Label Study of the Safety and Efficacy of Two Dose Levels of Interferon Alfacon-1 Plus Ribavirin Administered Daily for 48 Weeks Versus No-Treatment in Hepatitis C Infection Patients Who are Nonresponders to Previous Pegylated Interferon plus Ribavirin therapy." Intermune, 2005
Pozza, R. Sub-investigator. "Randomized Double Blind Multi-Center Study to Compare the Safety and Efficacy of Viramidine to Ribavirin in Treatment Nave Patients with Chronic Hepatitis C." Ribapharm, 2004
Pozza, R. Sub-investigator. "A multi-center, Randomized, Open-Label, Phase IIIb Study Investigating the Safety and Efficacy of Pegylated Interferon alfa-2a Plus Ribavirin for the Treatment of Chronic Hepatitis C Infection in HIV Infected Persons Who Have Failed to Achieve a Sustained Virologic Response Following Previous Interferon Therapy." Roche Pharmaceuticals, 2002
Pozza, R. Sub-investigator. "A randomized Clinical Trial Comparing Two Management Strategies for Treatment of Neutropenia and Anemia Associated With Pegylated Interferon Plus Ribavirin Treatment of Compensated Chronic Hepatitis C in Adult Subjects Infected With HIV." Schering Pharmaceuticals, 2002
Pozza, R. Sub-investigator. "PEG Intron + Ribavirin For the Treatment of Patients with Chronic Hepatitis C." Schering Pharmaceuticals, 2001
Pzza, R. Sub-investigator. "Comparison of PEG Interferon alfa-2b Plus Ribavirin Given as a Fixed Dose or on a Weight Optimized Basis for Treatment of Chronic Hepatitis C in Previously Untreated Adult Subjects. Schering Pharmaceuticals, 2001
Pozza, R. Sub-investigator. "An Open Labeled Randomized Parallel Group Study Comparing the Effectiveness of Procrit Administration Once Weekly vs. Standard of Care in Hepatitis C Patients Treated with Combination Ribavirin/Interferon alfa 2b." Ortho-Biotech Pharmaceuticals, 2000
Pozza, R. Sub-investigator. "A Randomized, Open Labeled Multi-Center Efficacy and Safety Study of Pegasys Plus Ribavirin, Pegasys Plus CellCept, Pegasys Plus Amantadine or Pegasys Plus Amantadine Plus Ribavirin in Patients with Chronic Hepatitis C Infection who Relapsed on Rebetron Therapy." Roche Pharmaceuticals, 2000
Pozza, R. Sub-investigator. "Pegylated Intron A Plus Ribavirin for Treatment of Patients with Rebetron Refractory Chronic Hepatitis C." Schering Pharmaceuticals, 2000
Pozza, R. Sub-investigator. "Phase II Study of Long-Term Pegylated Intron for Patients Who Have Failed to Respond to Rebetron/Interferon with Advanced Fibrosis and Cirrhosis Secondary to Hepatitis C." Schering Pharmaceuticals, 2000
Pozza, R. Sub-investigator. "Pilot Study of Sliding Scale vs. Induction/Ribavirin in Naïve Patients with Chronic Hepatitis C." Schering Pharmaceuticals, 2000
Pozza, R. Sub-investigator. "Randomizing Trial of High Dose Combination Ribavirin vs. Induction/Rebetron in Interferon Refractory or Interferon Relapse Patients with Hepatitis C." Schering Pharmaceuticals, 2000
Renee Pozza, PhD, CNS, CFNP, RN
Back to Profile
Research
Publications
Pozza R, Biando K, Maisey A, Hassanein T. "Interferon Response Rates in HCV Infected Dialysis Patients Awaiting Renal Transplantation." Abstract. Antiviral Therapies, (2004).
Pozza R, Albanese L, Medley K, Peeters R, Wahlstrom E, Hassanein T. "Prevalence of Hepatitis C in Community Based Screening Programs in Southern California." Abstact. Hepatology 32, A1566, 2000.
Pozza R, Chen P, Monson P, Behling C, Chatfield E, Krinsky M, Hassanein T. "Combination Therapy With or Without Induction for Non-Responders to Interferon Monotherapy." Abstact. Gastroenterology 18, A6492, 2000.
Pozza R, Albanese L, Medley K, Peeters R, Wahlstrom E, Hassanein T. "Prevalence of Hepatitis C in Community Based Screening Programs in Southern California." Abstact. Hepatology 32, A1566, 2000.
Pozza R, Chen P, Monson P, Behling C, Chatfield E, Krinsky M, Hassanein T. "Combination Therapy With or Without Induction for Non-Responders to Interferon Monotherapy." Abstact. Gastroenterology 18, A6492, 2000.
Presentations
Pozza R, Biando K, Maisey A, Hassanein T. "Interferon Response Rates in HCV Infected Dialysis Patients Awaiting Renal Transplantation," Viral Hepatitis Conference, Boston, MA, 2004.
Pozza R, Albanese L, Biando K, Hassanein T. "Severity of Liver Disease in ESRD Patients Awaiting Renal Transplantation," DDW, Poster, Orlando, FL, 2003
Pozza R, Albanese L, Biando K, Hassanein T. "Severity of Liver Disease in HCV Antibody Positive ESRD Patients Awaiting Renal Transplantation," Sigma Theta Tau International Annual Research Conference, Poster, Irvine CA, 2002
Pozza R, Albanese L, Biando K, Hassanein T. "Disease Severity in Hepatitis C Positive Dialysis Patients Awaiting Renal Transplantation," International Transplantation Nurses Society Annual Conference, Cambridge England, 2001
Back to ProfilePozza R, Albanese L, Biando K, Hassanein T. "Severity of Liver Disease in ESRD Patients Awaiting Renal Transplantation," DDW, Poster, Orlando, FL, 2003
Pozza R, Albanese L, Biando K, Hassanein T. "Severity of Liver Disease in HCV Antibody Positive ESRD Patients Awaiting Renal Transplantation," Sigma Theta Tau International Annual Research Conference, Poster, Irvine CA, 2002
Pozza R, Albanese L, Biando K, Hassanein T. "Disease Severity in Hepatitis C Positive Dialysis Patients Awaiting Renal Transplantation," International Transplantation Nurses Society Annual Conference, Cambridge England, 2001
Note: This information is current for the 2007-08 academic year. For additional information, please contact the appropriate office.
